Research analysts at StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a research note issued on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
GNCA opened at $0.00 on Friday. The firm has a market cap of $5,873.00, a price-to-earnings ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a 52 week low of $0.00 and a 52 week high of $0.00. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24.
Genocea Biosciences Company Profile
See Also
- Five stocks we like better than Genocea Biosciences
- What Are Dividend Champions? How to Invest in the Champions
- From PACs to Portfolios: Billionaire Bets and Investor Reactions
- How to Invest in the Best Canadian StocksÂ
- AppLovin Stock Quadruples: What’s Behind the Bullish Sentiment?
- How to Read Stock Charts for Beginners
- Battle of the Retailers: Who Comes Out on Top?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.